Publicaciones en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (35)

2021

  1. First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

    Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231

2019

  1. First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: A pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

    BMC Cancer, Vol. 19, Núm. 1

  2. Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: Retrospective analyses of two phase II randomised Spanish TTD trials

    ESMO Open, Vol. 4, Núm. 6

2017

  1. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain

    Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 667-681

  2. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)

    European Journal of Cancer, Vol. 81, pp. 191-202

  3. Supportive care in pancreatic ductal adenocarcinoma

    Clinical and Translational Oncology, Vol. 19, Núm. 11, pp. 1293-1302

2016

  1. Erratum to: SEOM guidelines for the treatment of gastric cancer 2015 (Clinical and Translational Oncology,(2015), 17, (996-1004), DOI:10.1007/s12094-015-1456-y)

    Clinical and Translational Oncology

  2. Prediction of non-muscle invasive bladder cancer outcomes assessed by innovative multimarker prognostic models

    BMC Cancer, Vol. 16, Núm. 1

2015

  1. Seom guidelines for the treatment of gastric cancer 2015

    Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 996-1004

2012

  1. Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

    PLoS ONE, Vol. 7, Núm. 10

2011

  1. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD)

    Critical Reviews in Oncology/Hematology, Vol. 77, Núm. 1, pp. 78-84

  2. Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04)

    Clinical and Translational Oncology, Vol. 13, Núm. 6, pp. 411-418

  3. Treatment recommendations for metastatic colorectal cancer

    Clinical and Translational Oncology, Vol. 13, Núm. 3, pp. 162-178

2010

  1. UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy

    British Journal of Cancer, Vol. 103, Núm. 4, pp. 581-589

2009

  1. Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: Comparative outcomes from the 03-TTD-01 phase III study

    Critical Reviews in Oncology/Hematology, Vol. 70, Núm. 2, pp. 134-144

  2. Retrospective study of efficacy and toxicity on patients older than 70 years within a randomized clinical trial of two cisplatin-based combinations in patients with small-cell lung cancer

    Lung Cancer, Vol. 63, Núm. 1, pp. 83-87

2008

  1. Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study

    Acta Oncologica, Vol. 47, Núm. 2, pp. 286-292

2007

  1. Guidelines for the detection and treatment of liver metastases of colorectal cancer

    Clinical and Translational Oncology, Vol. 9, Núm. 11, pp. 723-730

2006

  1. Guides for adjuvant treatment of colon cancer

    Clinical and Translational Oncology, Vol. 8, Núm. 2, pp. 98-102

  2. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: A Spanish Lung Cancer Group trial

    Annals of Oncology, Vol. 17, Núm. 3, pp. 467-472